JP3578761B2 - 表皮ケラチン細胞成長因子の治療目的での使用 - Google Patents
表皮ケラチン細胞成長因子の治療目的での使用 Download PDFInfo
- Publication number
- JP3578761B2 JP3578761B2 JP52218894A JP52218894A JP3578761B2 JP 3578761 B2 JP3578761 B2 JP 3578761B2 JP 52218894 A JP52218894 A JP 52218894A JP 52218894 A JP52218894 A JP 52218894A JP 3578761 B2 JP3578761 B2 JP 3578761B2
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- kgf
- cells
- prevention
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 title claims abstract description 173
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 title claims description 168
- 210000005175 epidermal keratinocyte Anatomy 0.000 title description 16
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 238000011282 treatment Methods 0.000 claims abstract description 76
- 210000004027 cell Anatomy 0.000 claims abstract description 62
- 210000004185 liver Anatomy 0.000 claims abstract description 27
- 210000004072 lung Anatomy 0.000 claims abstract description 20
- 230000035755 proliferation Effects 0.000 claims abstract description 18
- 230000004069 differentiation Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 238000001727 in vivo Methods 0.000 claims abstract description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 10
- 210000002510 keratinocyte Anatomy 0.000 claims abstract 2
- 210000005265 lung cell Anatomy 0.000 claims description 17
- 210000002919 epithelial cell Anatomy 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 12
- 210000002784 stomach Anatomy 0.000 claims description 9
- 210000003494 hepatocyte Anatomy 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 230000024245 cell differentiation Effects 0.000 claims description 5
- 230000007882 cirrhosis Effects 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 4
- 239000008365 aqueous carrier Substances 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 206010019799 Hepatitis viral Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 201000001862 viral hepatitis Diseases 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 208000000203 Hyaline Membrane Disease Diseases 0.000 claims description 2
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims description 2
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 208000000718 duodenal ulcer Diseases 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000006687 Esophageal Fistula Diseases 0.000 claims 2
- 206010065713 Gastric Fistula Diseases 0.000 claims 2
- 206010065835 Oesophageal fistula Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010067204 Airway burns Diseases 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010017865 Gastritis erosive Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 210000002175 goblet cell Anatomy 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 abstract description 21
- 241001465754 Metazoa Species 0.000 abstract description 18
- 210000001519 tissue Anatomy 0.000 abstract description 15
- 230000012010 growth Effects 0.000 abstract description 10
- 230000004071 biological effect Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 9
- 229940124597 therapeutic agent Drugs 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 210000000056 organ Anatomy 0.000 abstract description 6
- 229920001184 polypeptide Polymers 0.000 abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 4
- 230000002500 effect on skin Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 43
- 208000027418 Wounds and injury Diseases 0.000 description 35
- 206010052428 Wound Diseases 0.000 description 34
- 206010020718 hyperplasia Diseases 0.000 description 22
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 16
- 230000002390 hyperplastic effect Effects 0.000 description 14
- 210000001732 sebaceous gland Anatomy 0.000 description 14
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 13
- 230000000762 glandular Effects 0.000 description 12
- 210000003780 hair follicle Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 10
- 230000002062 proliferating effect Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 210000001156 gastric mucosa Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 7
- 230000000112 colonic effect Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 6
- 239000011800 void material Substances 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 240000007711 Peperomia pellucida Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000001120 cytoprotective effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000002183 duodenal effect Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 108010029560 keratinocyte growth factor receptor Proteins 0.000 description 4
- 230000002297 mitogenic effect Effects 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 230000003843 mucus production Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 241000446313 Lamella Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108020004518 RNA Probes Proteins 0.000 description 3
- 239000003391 RNA probe Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000037309 reepithelialization Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000000106 sweat gland Anatomy 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000012762 unpaired Student’s t-test Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000021017 Weight Gain Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- 210000003123 bronchiole Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 210000001100 crypt cell Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000000442 hair follicle cell Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000012753 partial hepatectomy Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011555 rabbit model Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 241000287227 Fringillidae Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007893 endotoxin activity Effects 0.000 description 1
- 231100000174 enterotoxicity Toxicity 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000007967 glucose restriction Effects 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000004378 sebocyte Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 238000009732 tufting Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4074293A | 1993-03-26 | 1993-03-26 | |
| US08/040,742 | 1993-03-26 | ||
| PCT/US1994/003208 WO1994023032A1 (en) | 1993-03-26 | 1994-03-24 | Therapeutic uses of keratinocyte growth factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002526026A JP2002526026A (ja) | 2002-08-13 |
| JP3578761B2 true JP3578761B2 (ja) | 2004-10-20 |
Family
ID=21912689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52218894A Expired - Lifetime JP3578761B2 (ja) | 1993-03-26 | 1994-03-24 | 表皮ケラチン細胞成長因子の治療目的での使用 |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0619370B1 (no) |
| JP (1) | JP3578761B2 (no) |
| KR (1) | KR100390340B1 (no) |
| CN (1) | CN1064710C (no) |
| AT (1) | ATE183233T1 (no) |
| AU (1) | AU707340B2 (no) |
| CA (1) | CA2159109C (no) |
| CZ (1) | CZ285996B6 (no) |
| DE (1) | DE69419958T2 (no) |
| DK (1) | DK0619370T3 (no) |
| ES (1) | ES2136673T3 (no) |
| FI (1) | FI954541A (no) |
| GR (1) | GR3031509T3 (no) |
| HU (1) | HU220641B1 (no) |
| IL (4) | IL109122A (no) |
| NO (1) | NO953781L (no) |
| NZ (1) | NZ263967A (no) |
| RU (1) | RU2146148C1 (no) |
| SG (1) | SG49841A1 (no) |
| SI (1) | SI0619370T1 (no) |
| SK (1) | SK281674B6 (no) |
| UA (1) | UA46706C2 (no) |
| WO (1) | WO1994023032A1 (no) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020111047A1 (ja) | 2018-11-27 | 2020-06-04 | 株式会社海月研究所 | 頭皮頭髪用組成物 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN271295A0 (en) * | 1995-05-02 | 1995-05-25 | Gropep Pty Ltd | Method of treatment |
| EE03975B1 (et) * | 1994-10-13 | 2003-02-17 | Amgen Inc. | Keratinotsüüdi kasvufaktori analoogid |
| AU708868B2 (en) * | 1995-02-14 | 1999-08-12 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US6693077B1 (en) | 1995-02-14 | 2004-02-17 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US6077692A (en) | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US7232667B2 (en) | 1995-02-14 | 2007-06-19 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 polynucleotides |
| JPH11513405A (ja) * | 1995-10-11 | 1999-11-16 | カイロン コーポレイション | 創傷治癒のためのｐｄｇｆ、ｋｇｆ、ｉｇｆ、およびｉｇｆｂｐの配合物 |
| GB9619660D0 (en) * | 1996-09-20 | 1996-11-06 | Scient Hospital Suppl Int Ltd | Prevention of gastrointestinal damage |
| SI0941110T1 (en) * | 1996-10-15 | 2004-06-30 | Amgen Inc. | Uses of keratinocyte growth factor-2 |
| US6743422B1 (en) | 1996-10-15 | 2004-06-01 | Amgen, Inc. | Keratinocyte growth factor-2 products |
| PT941110E (pt) * | 1996-10-15 | 2004-07-30 | Amgen Inc | Utilizacao do factor 2 de crescimento dos ceratinocitos |
| US20010006939A1 (en) * | 1997-10-03 | 2001-07-05 | Ralph W. Niven | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| US6228839B1 (en) * | 1997-12-19 | 2001-05-08 | Emory University | Use of keratinocyte growth factor to improve oxidative status |
| US6869927B1 (en) | 1997-12-22 | 2005-03-22 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| NZ505324A (en) | 1997-12-22 | 2002-11-26 | Human Genome Sciences Inc | Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration |
| EP1054900A4 (en) | 1998-02-13 | 2004-12-22 | Human Genome Sciences Inc | THERAPEUTIC USE OF THE KERATINOCTENT GROWTH FACTOR-2 |
| US6335317B1 (en) | 1998-04-10 | 2002-01-01 | Emory University | Use of gut-trophic growth factors to improve oxidative status |
| AU2001243657A1 (en) | 2000-03-20 | 2001-10-03 | Osi Pharmaceuticals, Inc | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| CA2437270A1 (en) * | 2001-02-06 | 2002-08-15 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified keratinocyte growth factor (kgf) with reduced immunogenicity |
| US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| EP1789138A2 (en) * | 2004-09-13 | 2007-05-30 | University Of Southampton | Growth factor treatment for asthma |
| CN101822821B (zh) * | 2010-04-27 | 2013-01-23 | 复旦大学附属中山医院 | 角质细胞生长因子-2在制备防治肺损伤的药物中的应用 |
| CN104707164B (zh) * | 2015-03-31 | 2017-01-18 | 中国人民解放军军事医学科学院基础医学研究所 | 一种复合壳聚糖水凝胶敷料及其制备方法和应用 |
| CN106226511B (zh) * | 2016-07-28 | 2018-04-06 | 苏州金盟生物技术有限公司 | 一种重组人角质细胞生长因子生物学活性检测方法 |
| CN107753932A (zh) * | 2016-08-22 | 2018-03-06 | 中国辐射防护研究院 | Kgf在制备治疗或预防放射性肠炎药物中的用途 |
| KR20210114646A (ko) * | 2020-03-11 | 2021-09-24 | (주)메디코스바이오텍 | 성장인자를 함유하는 탈모 치료 또는 모발 성장 촉진용 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20022681B (en) * | 1989-01-31 | 2002-04-25 | Aaronson Us Stuart A | Protein KFG, Antibodies, Pharmaceutical Composition, Their Use, recombinant DNA, Cell, Method for Discoveries and Production of Proteins, Method for Stimulation of Epithelial Cells Growth |
| JPH04224522A (ja) * | 1990-04-27 | 1992-08-13 | Merck & Co Inc | 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法 |
| AU1462392A (en) * | 1991-02-22 | 1992-09-15 | Amgen, Inc. | Use of gm-csf and g-csf to promote accelerated wound healing |
-
1994
- 1994-03-24 CN CN94192037A patent/CN1064710C/zh not_active Expired - Lifetime
- 1994-03-24 IL IL10912294A patent/IL109122A/en not_active IP Right Cessation
- 1994-03-24 WO PCT/US1994/003208 patent/WO1994023032A1/en active IP Right Grant
- 1994-03-24 SK SK1185-95A patent/SK281674B6/sk not_active IP Right Cessation
- 1994-03-24 IL IL137581A patent/IL137581A/en not_active IP Right Cessation
- 1994-03-24 CA CA002159109A patent/CA2159109C/en not_active Expired - Lifetime
- 1994-03-24 HU HU9502800A patent/HU220641B1/hu unknown
- 1994-03-24 JP JP52218894A patent/JP3578761B2/ja not_active Expired - Lifetime
- 1994-03-24 CZ CZ952482A patent/CZ285996B6/cs not_active IP Right Cessation
- 1994-03-24 RU RU95117959A patent/RU2146148C1/ru active
- 1994-03-24 AU AU65243/94A patent/AU707340B2/en not_active Expired
- 1994-03-24 UA UA95104698A patent/UA46706C2/uk unknown
- 1994-03-24 KR KR1019950704154A patent/KR100390340B1/ko not_active IP Right Cessation
- 1994-03-24 NZ NZ263967A patent/NZ263967A/en not_active IP Right Cessation
- 1994-03-25 DK DK94104804T patent/DK0619370T3/da active
- 1994-03-25 EP EP94104804A patent/EP0619370B1/en not_active Expired - Lifetime
- 1994-03-25 ES ES94104804T patent/ES2136673T3/es not_active Expired - Lifetime
- 1994-03-25 DE DE69419958T patent/DE69419958T2/de not_active Expired - Lifetime
- 1994-03-25 SI SI9430265T patent/SI0619370T1/xx unknown
- 1994-03-25 SG SG1996007376A patent/SG49841A1/en unknown
- 1994-03-25 AT AT94104804T patent/ATE183233T1/de active
-
1995
- 1995-09-25 NO NO953781A patent/NO953781L/no not_active Application Discontinuation
- 1995-09-25 FI FI954541A patent/FI954541A/fi unknown
-
1999
- 1999-10-13 GR GR990402604T patent/GR3031509T3/el unknown
-
2000
- 2000-07-30 IL IL13758100A patent/IL137581A0/xx unknown
-
2004
- 2004-04-22 IL IL16156804A patent/IL161568A0/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020111047A1 (ja) | 2018-11-27 | 2020-06-04 | 株式会社海月研究所 | 頭皮頭髪用組成物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3578761B2 (ja) | 表皮ケラチン細胞成長因子の治療目的での使用 | |
| US5965530A (en) | Therapeutic uses of keratinocyte growth factor | |
| JPS63502985A (ja) | 角膜基質創傷の治療のための組成物 | |
| JP2003504025A (ja) | トレフォイルペプチドの送達 | |
| BRPI0708791A2 (pt) | medicamentos e proteÍnas | |
| EP0492614A2 (en) | Epitheliocyte growth accelerator | |
| PT804479E (pt) | Método para o tratamento de diabetes mellitus utilizando kgf | |
| JP2003532742A (ja) | 神経損傷の修復 | |
| Pereira et al. | Liposomal gene transfer of keratinocyte growth factor improves wound healing by altering growth factor and collagen expression | |
| Berlanga | Heberprot-P: antecedentes experimentales y bases farmacológicas | |
| US9060977B2 (en) | Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation | |
| US11622964B2 (en) | Method for destroying cellular mechanical homeostasis and promoting regeneration and repair of tissues and organs, and use thereof | |
| CN111184856A (zh) | 小分子多肽tp-7在制备治疗慢性肾脏病药物中的用途 | |
| Schouten et al. | Treatment of juvenile laryngeal papillomatosis with two types of interferon | |
| KR20060052692A (ko) | 고콜레스테롤혈증 또는 당뇨병과 관련된 혈관형성 결함을치료하기 위한 섬유모세포 성장 인자를 코딩하는플라스미드 | |
| CN114432332B (zh) | circUTRN在制备治疗心力衰竭药物中的应用、重组载体和治疗心力衰竭的药物 | |
| AU703793B2 (en) | Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF) | |
| Tchorzewski et al. | Characterization of an aFGF gene expression vector with therapeutic potential | |
| JP3034032B2 (ja) | 腸疾患用薬剤 | |
| Thompson | Differential effect of growth factors on intestinal wall components | |
| US20060183680A1 (en) | Remedy for ischemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040303 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040622 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040714 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070723 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080723 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080723 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090723 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090723 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100723 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110723 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110723 Year of fee payment: 7 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110723 Year of fee payment: 7 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110723 Year of fee payment: 7 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110723 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120723 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120723 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130723 Year of fee payment: 9 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |